Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($1.36), $0.31 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $4.9 million.

Outlook

We expect to fund advancements across all stages of our development pipeline, including investment towards the key program milestones anticipated in 2017 and 2018. We anticipate our full year 2017 operating loss, excluding share-based compensation, will be in the range of $195.0 to $205.0 million. The actual amount could be above or below this forecast as a result of a variety of factors impacting our business, including business development transactions, the timing and cost of clinical and non-clinical studies associated with our priority programs, and net product sales of VIBATIV

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.